Notably, because disease-free survival (DFS) is often used to describe prognosis in breast cancer clinical work, we also analyzed disease-free interval (DFI) of ELOVL2-AS1 according to TCGA guidelines (Kaplan–Meier [KM] log rank of p < 0.001) (Fig. 1A), which is consistent with the results of overall survival (OS) (Fig. S1). The gene discussed is ELOVL2; the disease is breast carcinoma.